These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31076321)

  • 1. The pathogenesis of post-primary tuberculosis. A game changer for vaccine development.
    Hunter R; Actor J
    Tuberculosis (Edinb); 2019 May; 116S():S114-S117. PubMed ID: 31076321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactoferrin enhances efficacy of the BCG vaccine: comparison between two inbred mice strains (C57BL/6 and BALB/c).
    Hwang SA; Arora R; Kruzel ML; Actor JK
    Tuberculosis (Edinb); 2009 Dec; 89 Suppl 1():S49-54. PubMed ID: 20006305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
    Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
    Front Immunol; 2020; 11():575504. PubMed ID: 33117374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing efficacy of BCG/lactoferrin primary vaccination versus booster regimen.
    Hwang SA; Welsh KJ; Boyd S; Kruzel ML; Actor JK
    Tuberculosis (Edinb); 2011 Dec; 91 Suppl 1():S90-5. PubMed ID: 22088320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis.
    Hwang SA; Wilk KM; Budnicka M; Olsen M; Bangale YA; Hunter RL; Kruzel ML; Actor JK
    Vaccine; 2007 Sep; 25(37-38):6730-43. PubMed ID: 17698261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of interferon-gamma and tumour necrosis factor-alpha messenger RNA does not correlate with protection in guinea pigs challenged with virulent Mycobacterium tuberculosis by the respiratory route.
    Jeevan A; Bonilla DL; McMurray DN
    Immunology; 2009 Sep; 128(1 Suppl):e296-305. PubMed ID: 19016908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines.
    Mascart F; Locht C
    Expert Rev Vaccines; 2015; 14(12):1573-85. PubMed ID: 26517361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHO expressed recombinant human lactoferrin as an adjuvant for BCG.
    Hwang SA; Kruzel ML; Actor JK
    Int J Immunopathol Pharmacol; 2015 Dec; 28(4):452-68. PubMed ID: 26315722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen.
    Fukui M; Shinjo K; Umemura M; Shigeno S; Harakuni T; Arakawa T; Matsuzaki G
    Microbiol Immunol; 2015 Dec; 59(12):735-43. PubMed ID: 26577130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycobacterium bovis BCG vaccination augments interleukin-8 mRNA expression and protein production in guinea pig alveolar macrophages infected with Mycobacterium tuberculosis.
    Lyons MJ; Yoshimura T; McMurray DN
    Infect Immun; 2002 Oct; 70(10):5471-8. PubMed ID: 12228272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium tuberculosis virulence: insights and impact on vaccine development.
    Delogu G; Provvedi R; Sali M; Manganelli R
    Future Microbiol; 2015; 10(7):1177-94. PubMed ID: 26119086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.
    Hwang SA; Wilk K; Kruzel ML; Actor JK
    Vaccine; 2009 May; 27(23):3026-34. PubMed ID: 19428915
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Ryndak MB; Laal S
    Front Cell Infect Microbiol; 2019; 9():299. PubMed ID: 31497538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous Boost Following
    Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
    Front Immunol; 2018; 9():2439. PubMed ID: 30425711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCG-mediated protection against M. tuberculosis is sustained post-malaria infection independent of parasite virulence.
    Tangie E; Walters A; Hsu NJ; Fisher M; Magez S; Jacobs M; Keeton R
    Immunology; 2022 Feb; 165(2):219-233. PubMed ID: 34775598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.
    Coppola M; Ottenhoff TH
    Semin Immunol; 2018 Oct; 39():88-101. PubMed ID: 30327124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis.
    Hwang SA; Kruzel ML; Actor JK
    Int Immunopharmacol; 2005 Mar; 5(3):591-9. PubMed ID: 15683854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion of PPARĪ³ in lung macrophages provides an immunoprotective response against M. tuberculosis infection in mice.
    Guirado E; Rajaram MV; Chawla A; Daigle J; La Perle KM; Arnett E; Turner J; Schlesinger LS
    Tuberculosis (Edinb); 2018 Jul; 111():170-177. PubMed ID: 30029904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis.
    Horwitz MA; Harth G
    Infect Immun; 2003 Apr; 71(4):1672-9. PubMed ID: 12654780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of new tuberculosis vaccine in children.
    Pang Y; Zhao A; Cohen C; Kang W; Lu J; Wang G; Zhao Y; Zheng S
    Hum Vaccin Immunother; 2016 Apr; 12(4):960-70. PubMed ID: 27002369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.